Grufity logoGrufity logo

Regeneron Pharmaceuticals Inc Stock Research

REGN

749.75USD-10.55(-1.39%)Delayed

Market Summary

USD749.75-10.55
Delayed
-1.39%

REGN Alerts

REGN Stock Price

REGN RSI Chart

REGN Valuation

Market Cap

80.1B

Price/Earnings (Trailing)

18.47

Price/Sales (Trailing)

6.58

EV/EBITDA

14.65

Price/Free Cashflow

15.98

REGN Price/Sales (Trailing)

REGN Profitability

EBT Margin

39.91%

Return on Equity

19.14%

Return on Assets

14.85%

Free Cashflow Yield

6.26%

REGN Fundamentals

REGN Revenue

Revenue (TTM)

12.2B

Revenue Y/Y

-31.05%

Revenue Q/Q

16.29%

REGN Earnings

Earnings (TTM)

4.3B

Earnings Y/Y

-46.29%

Earnings Q/Q

-9.01%

Price Action

52 Week Range

538.01800.48
(Low)(High)

Last 7 days

2.0%

Last 30 days

-0.5%

Last 90 days

4.0%

Trailing 12 Months

14.2%

REGN Financial Health

Current Ratio

5.06

Debt/Equity

0.07

Debt/Cashflow

3.75

REGN Investor Care

Shares Dilution (1Y)

0.66%

Diluted EPS (TTM)

38.22

Peers (Alternatives to Regeneron Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
304.8B
1.4B
-3.73% 61.04%
-152.12
215.28
20.37% -37.45%
275.0B
58.1B
0.21% 1.63%
23.24
4.74
3.30% 2.55%
80.1B
12.2B
-0.48% 14.17%
18.47
6.58
-24.26% -46.28%
77.3B
8.9B
-1.64% 19.14%
23.26
8.65
17.91% 41.84%
23.5B
1.0B
-16.46% 21.47%
-20.78
22.66
22.88% -32.64%
13.2B
933.0M
21.02% 90.98%
-18.71
14.11
32.93% -67.99%
10.1B
1.9B
-15.04% 21.63%
13.93
5.23
14.88% 52.86%
MID-CAP
4.5B
504.0K
-6.48% 165.34%
-15.07
2.5K
-66.53% -22.12%
2.8B
363.3M
-7.03% -36.05%
-3.99
7.77
3.39% -55.81%
2.7B
204.0M
2.71% -22.88%
-4.84
13.22
13.30% 13.44%
2.5B
12.4M
-10.70% -44.17%
-3.35
199.44
- -27.34%
SMALL-CAP
1.6B
191.8M
-7.72% 90.19%
24.49
8.55
43.59% 60.82%
429.6M
93.0M
-0.16% -22.78%
-2.25
4.62
-19.83% -30.37%
24.0M
-
-31.83% 665.59%
-0.57
19.11
-77.61% 7.22%
3.5M
94.6M
-15.04% 9.81%
-0.01
0.04
34.30% -80.65%

Financials for Regeneron Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-11.2%12,17313,71014,22716,50816,072
  S&GA Expenses5.0%2,1162,0151,9311,8691,825
  R&D Expenses9.3%3,5933,2873,0412,9612,860
Costs and Expenses-0.6%7,4347,4787,3727,4167,125
EBITDA-17.9%5,2606,4096,6969,4839,669
EBITDA Margin-7.6%0.43*0.47*0.45*0.57*0.60*
Earnings Before Taxes-19.5%4,8596,0386,3449,1349,326
EBT Margin-9.4%0.40*0.44*0.42*0.55*0.58*
Interest Expenses5.9%59.0056.0055.0056.0057.00
Net Income-19.2%4,3385,3705,6877,9348,075
Net Income Margin-9.0%0.36*0.39*0.38*0.48*0.50*
Free Cahsflow-11.5%5,0155,6688,4528,5157,081
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets5.6%29,21527,67827,20626,34925,435
  Current Assets3.0%15,88415,42915,53014,30614,015
    Cash Equivalents-11.0%3,1063,4913,3953,3462,886
  Inventory-0.4%2,4022,4122,2191,9921,951
  Net PPE1.8%3,7043,6383,5563,482-
Liabilities5.0%6,5516,2396,5186,4346,666
  Current Liabilities9.1%3,1412,8793,0343,0083,933
  Long Term Debt-10.3%1,5131,6861,887--
    LT Debt, Non Current0.0%1,9811,9811,9811,9801,980
Shareholder's Equity5.7%22,66421,43920,68819,91518,769
  Retained Earnings5.4%23,30722,11020,79419,94218,968
  Additional Paid-In Capital4.5%9,9499,5189,1208,7548,088
Shares Outstanding-0.9%107108107--
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-11.5%5,0155,6688,4528,5157,081
  Share Based Compensation6.4%725681652638602
Cashflow From Investing3.9%-3,784-3,939-6,570-6,031-5,384
Cashflow From Financing39.5%-1,009-1,668-557-574-1,005
  Buy Backs-17.5%2,0832,5261,8031,6981,645

Risks for REGN

What is the probability of a big loss on REGN?

71.2%


Probability that Regeneron Pharmaceuticals stock will be more than 20% underwater in next one year

35.8%


Probability that Regeneron Pharmaceuticals stock will be more than 30% underwater in next one year.

6.5%


Probability that Regeneron Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does REGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Regeneron Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for REGN

Cumulative Returns on REGN

16.0%


10-Year Cumulative Returns

10.9%


7-Year Cumulative Returns

17.2%


5-Year Cumulative Returns

17.8%


3-Year Cumulative Returns

What are the long-term rolling returns for REGN?

FIve years rolling returns for Regeneron Pharmaceuticals.

Annualized Returns

Which funds bought or sold REGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-23.00
-224,477
937,523
0.03%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-1.83
1,789,050
65,144,100
0.07%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
1,910
33,910
-%
2023-03-10
MATHER GROUP, LLC.
added
3.41
19,139
241,139
-%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
unchanged
-
14,671
324,671
0.05%
2023-03-06
OLD MISSION CAPITAL LLC
sold off
-100
-338,000
-
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-6.7
-1,274,000
54,461,000
0.27%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
new
-
202,017
202,017
0.01%
2023-03-03
TIAA, FSB
added
50.62
735,350
2,009,350
0.01%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
9,088,600
9,088,600
0.11%

1–10 of 48

Latest Funds Activity

Are funds buying REGN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own REGN
No. of Funds

Regeneron Pharmaceuticals News

Nasdaq

Guru Fundamental Report for REGN.

Nasdaq,
29 minutes ago

London South East

Investor's Business Daily

Investor's Business Daily

Schedule 13G FIlings of Regeneron Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital world investors
5.9%
6,315,819
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.15%
8,722,448
SC 13G/A
Feb 03, 2023
blackrock inc.
8.6%
9,166,817
SC 13G/A
Jan 11, 2023
jpmorgan chase & co
5.6%
6,101,044
SC 13G
Feb 11, 2022
capital world investors
5.1%
5,391,870
SC 13G/A
Feb 10, 2022
vanguard group inc
7.72%
8,158,515
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
9.1%
9,610,871
SC 13G/A
Feb 16, 2021
capital world investors
6.7%
7,017,122
SC 13G/A

REGN Fair Value

Regeneron Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Regeneron Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

1024.59

36.66%

1399.74

86.69%

1972.26

163.06%

2986.22

298.30%

3604.06

380.70%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Regeneron Pharmaceuticals Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Regeneron Pharmaceuticals

View All Filings
Date Filed Form Type Document
Mar 14, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Feb 24, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 13, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 08, 2023
4
Insider Trading
Feb 08, 2023
4
Insider Trading

Latest Insider Trading transactions for REGN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-10
LAROSA JOSEPH J
gifted
-
-
-1,006
evp general counsel and secret
2023-03-01
RYAN ARTHUR F
sold
-76,249
762
-100
-
2023-03-01
McCourt Marion
acquired
409,706
372
1,100
evp commercial
2023-03-01
McCourt Marion
sold
-835,879
759
-1,100
evp commercial
2023-02-22
VAGELOS P ROY
sold (taxes)
-21,758,400
750
-29,005
-
2023-02-22
VAGELOS P ROY
acquired
11,493,300
270
42,500
-
2023-02-12
McCourt Marion
sold (taxes)
-959,271
751
-1,276
evp commercial
2023-02-07
McCourt Marion
sold
-769,040
769
-1,000
evp commercial
2023-02-07
McCourt Marion
acquired
372,460
372
1,000
evp commercial
2023-02-06
GOLDSTEIN JOSEPH L
acquired
1,743,920
482
3,613
-

1–10 of 50

Leonard S. Schleifer
10400
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Revenues$ 2,936.2$ 3,452.8$ 8,758.5$ 11,120.0
Expenses:    
Research and development911.3665.42,549.42,122.5
Acquired in-process research and development0.00.0225.10.0
Selling, general, and administrative529.1445.01,455.41,265.3
Other operating (income) expense, net(45.7)42.0(83.3)(29.8)
Costs and expenses, total1,712.51,605.65,166.44,812.9
Income from operations1,223.71,847.23,592.16,307.1
Other income (expense):    
Other income (expense), net301.4(16.4)(16.0)558.5
Interest expense(15.3)(14.2)(42.0)(43.2)
Total other income (expense)286.1(30.6)(58.0)515.3
Income before income taxes1,509.81,816.63,534.16,822.4
Income tax expense194.1184.4392.8976.1
Net income$ 1,315.7$ 1,632.2$ 3,141.3$ 5,846.3
Net income per share - basic (in dollars per share)$ 12.31$ 15.37$ 29.30$ 55.42
Net income per share - diluted (in dollars per share)$ 11.66$ 14.33$ 27.73$ 52.29
Weighted average shares outstanding - basic (in shares)106.9106.2107.2105.5
Weighted average shares outstanding - diluted (in shares)112.8113.9113.3111.8
Statements of Comprehensive Income    
Net income$ 1,315.7$ 1,632.2$ 3,141.3$ 5,846.3
Other comprehensive income (loss), net of tax:    
Unrealized loss on debt securities(51.3)(6.4)(249.9)(20.5)
Unrealized gain on cash flow hedges0.00.21.00.7
Comprehensive income1,264.41,626.02,892.45,826.5
Net product sales    
Revenues:    
Revenues1,801.42,279.95,194.48,142.0
Expenses:    
Cost of goods, collaboration and contract manufacturing141.3238.8497.8961.4
Collaboration revenue    
Revenues:    
Revenues1,050.61,073.93,326.72,783.0
Other revenue    
Revenues:    
Revenues84.299.0237.4195.0
Cost of collaboration and contract manufacturing    
Expenses:    
Cost of goods, collaboration and contract manufacturing$ 176.5$ 214.4$ 522.0$ 493.5

REGN Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 3,491.3$ 2,885.6
Marketable securities3,530.42,809.1
Accounts receivable, net5,548.36,036.5
Inventories2,412.21,951.3
Prepaid expenses and other current assets446.4332.4
Total current assets15,428.614,014.9
Marketable securities5,968.66,838.0
Property, plant, and equipment, net3,704.23,482.2
Intangible assets, net804.16.7
Deferred tax assets1,452.1876.9
Other noncurrent assets320.2216.1
Total assets27,677.825,434.8
Current liabilities:  
Accounts payable535.6564.0
Accrued expenses and other current liabilities1,796.42,206.8
Finance lease liabilities0.0719.7
Deferred revenue547.2442.0
Total current liabilities2,879.23,932.5
Long-term debt1,981.11,980.0
Finance lease liabilities720.00.0
Deferred revenue60.173.3
Other noncurrent liabilities598.6680.2
Total liabilities6,239.06,666.0
Stockholders' equity:  
Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none0.00.0
Additional paid-in capital9,518.28,087.5
Retained earnings22,109.618,968.3
Accumulated other comprehensive loss(275.1)(26.2)
Treasury Stock, at cost; 22.0 shares in 2022 and 19.4 shares in 2021(9,914.0)(8,260.9)
Total stockholders' equity21,438.818,768.8
Total liabilities and stockholders' equity27,677.825,434.8
Class A Stock  
Stockholders' equity:  
Common stock0.00.0
Common Stock  
Stockholders' equity:  
Common stock$ 0.1$ 0.1